Straits Times Index
3,287.75 -5.38 (-0.16%) S&P 500
5,008.24 -63.39 (-1.25%) Dow
37,845.11 -615.81 (-1.60%) Nasdaq
15,441.88 -270.87 (-1.72%) Bitcoin USD
63,802.01 -865.30 (-1.34%) CMC Crypto 200
1,378.18 -4.39 (-0.32%)
VRTX Jun 2024 340.000 put
| Previous close | 1.4300 |
| Open | 1.4300 |
| Bid | 1.7000 |
| Ask | 2.0000 |
| Strike | 340.00 |
| Expiry date | 2024-06-21 |
| Day's range | 1.4300 - 1.4300 |
| Contract range | N/A |
| Volume | |
| Open interest | 127 |
- Reuters
Regeneron to collaborate on gene editing therapies with Doudna-founded Mammoth
Regeneron Pharmaceuticals and Mammoth Biosciences will collaborate to research, develop and commercialize gene editing therapies for multiple diseases, the companies said on Thursday. Mammoth's CRISPR-based gene editing platform and Regeneron's delivery technologies will be used to create disease-modifying medicines that can be delivered to tissues beyond the liver. CRISPR, discovered by Jennifer Doudna and CRISPR Therapeutics co-founder Emmanuelle Charpentier, uses molecular "scissors" to trim faulty parts of genes that can then be disabled or replaced with new strands of normal DNA.
ZacksVertex (VRTX), TreeFrog Sign Deal for Diabetes Cell Therapies
Vertex (VRTX) signs a collaboration agreement with TreeFrog to utilize the latter's C-Stem technology in order to optimize the production of its T1D cell therapies.
CNW GroupVERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and TreeFrog Therapeutics today announced that Vertex has obtained an exclusive license to TreeFrog's proprietary cell manufacturing technology, C-StemTM, to optimize production of Vertex's cell therapies for type 1 diabetes (T1D). TreeFrog and Vertex will collaborate to scale-up TreeFrog's process to produce and amplify cells for Vertex's T1D therapies.
